Regeneron secures $1 billion upfront and profit-share deal with Sanofi on four new antibodies
Regeneron and Sanofi have expanded their 17-year collaboration to co-develop and co-commercialize four new long-acting antibodies...
Nike revenue falls 4 percent as Greater China and direct sales weaken; company cuts fiscal 2027 outlook to high-single-digit decline
Nike's first quarter revenue dropped 4 percent to $11.2 billion, driven by declines in Greater China...
Regeneron ties executive pay to pipeline output, not revenue growth, signaling confidence in R&D engine
Regeneron's board approved a 10-year performance award for its two co-founders that pays out almost entirely...
Moderna Brings Back Operations Chief as Oncology Push Demands Manufacturing Scale
Moderna has created a Chief Operating Officer role and named Juan Andres to fill it, effective...
Adobe names Chakravarthy CEO as Narayen steps to executive chair
Adobe's board has named Anil Chakravarthy president and chief executive officer effective December 1, 2026, replacing...
AbbVie Reaffirms 2026 Guidance After Closing $10.9 Billion Apogee Acquisition
AbbVie completed its acquisition of Apogee Therapeutics for $10.9 billion in cash, adding two late-stage immunology...
Moderna raises $2.6 billion in zero-coupon convertibles as revenue collapses, betting oncology turnaround
Moderna priced a $2.6 billion offering of convertible senior notes due 2032 on August 28, 2026,...
Caterpillar renews three-year credit facility with unchanged $4 billion commitment as borrowing costs shift to SOFR
Caterpillar Inc. has executed a fifth amendment to its revolving credit agreement, dated August 27, 2026,...
Boeing renews 364-day credit line as operating margin stays thin at 4.8%
Boeing has executed a new 364-day revolving credit agreement dated August 24, 2026, replacing its prior...
Walmart’s operating income surges 28.8% as tariff refunds and eCommerce gains offset pricing pressure
Walmart reported second-quarter revenue of $187.9 billion, up 5.9% from the prior year (5.1% in constant...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.